Trials / Completed
CompletedNCT06086886
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants
A Phase 1, Double-blinded, Randomized, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of BMS-986454 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986454 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986454 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2023-11-16
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
- First posted
- 2023-10-17
- Last updated
- 2025-03-24
Locations
2 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06086886. Inclusion in this directory is not an endorsement.